{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T03:49:32Z","timestamp":1776829772117,"version":"3.51.2"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.critrevonc.2023.103923","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T11:49:32Z","timestamp":1674474572000},"page":"103923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1427-4726","authenticated-orcid":false,"given":"Marouane","family":"Maaroufi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2023.103923_bib1","first-page":"39","article-title":"Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk hodgkin lymphoma","author":"A","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib2","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.2013.53.2069","article-title":"Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"32","author":"Advani","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/hon.2897","article-title":"Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: multicenter retrospective study","author":"Akay","year":"2021","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib4","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/hon.2383","article-title":"Brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma. The Hellenic experience","volume":"36","author":"Angelopoulou","year":"2018","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib6","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ajh.25071","article-title":"Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management","volume":"93","author":"Ansell","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2023.103923_bib8","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkmate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib10","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2021-147881","article-title":"Five-year follow-up of keynote-087: pembrolizumab monotherapy in relapsed\/refractory classical hodgkin lymphoma (R\/R cHL)","volume":"138","author":"Armand","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib11","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ajh.24792","article-title":"Outcomes of patients with relapsed\/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: a retrospective analysis","volume":"92","author":"Bair","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib13","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2019004701","article-title":"A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"136","author":"Bartlett","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","article-title":"Coinhibitory pathways in immunotherapy for cancer","volume":"34","author":"Baumeister","year":"2016","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib15","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1185\/03007995.2015.1048208","article-title":"Brentuximab vedotin compared with other therapies in relapsed\/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis","volume":"31","author":"Bonthapally","year":"2015","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.critrevonc.2023.103923_bib16","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdg175","article-title":"An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab","volume":"14","author":"Boye","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/ejh.12973","article-title":"Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: a Germany and United Kingdom retrospective study","volume":"99","author":"Br\u00f6ckelmann","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib18","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/blood-2021-145111","article-title":"Pembrolizumab (PEM) added to ICE chemotherapy results in high complete metabolic response rates in relapsed\/refractory classic Hodgkin Lymphoma (cHL): a multi-institutional phase II trial","volume":"138","author":"Bryan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bjh.14001","article-title":"Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma","volume":"176","author":"Cencini","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib22","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib23","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMra0708875","article-title":"Monoclonal antibody therapy for b-cell non-Hodgkin\u2019s lymphoma","volume":"359","author":"Cheson","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2023.103923_bib25","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/S2352-3026(20)30275-1","article-title":"Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial","volume":"7","author":"Cheson","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib26","unstructured":"ClinicalTrials.gov. National Library of Medicine (U.S). (2013 July 11 -). Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma. Identified NCT01896999. Accessed August 10, 2022c from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01896999\u3009."},{"key":"10.1016\/j.critrevonc.2023.103923_bib27","unstructured":"ClinicalTrials.gov. National Library of Medicine (U.S). (2016 January 22 -). HD21 for advanced stages. Identified NCT02661503. Accessed July 15, 2022a from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02661503\u3009."},{"key":"10.1016\/j.critrevonc.2023.103923_bib28","unstructured":"ClinicalTrials.gov. National Library of Medicine (U.S). (2020 December 28 -). Brentuximab Vedotin in Early Stage Hodgkin Lymphoma (RADAR). Identified NCT04685616. Accessed July 27, 2022b from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04685616\u3009."},{"key":"10.1016\/j.critrevonc.2023.103923_bib29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2023.103923_bib30","first-page":"1","article-title":"Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group","author":"Damaschin","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2023.103923_bib31","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib32","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","article-title":"Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin\u2019s disease and lymphocyte-rich classical Hodgkin\u2019s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin\u2019s Disease","volume":"17","author":"Diehl","year":"1999","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib33","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-06-361055","article-title":"Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"118","author":"Eichenauer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib34","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(17)30696-4","article-title":"Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin\u2019s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group","volume":"18","author":"Eichenauer","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib35","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","article-title":"Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial","volume":"101","author":"Ekstrand","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib36","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged \u226560 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study","author":"Evens","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2023.103923_bib37","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/bjh.14898","article-title":"Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting","volume":"179","author":"Eyre","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib38","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood-2017-02-766121","article-title":"Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma","volume":"130","author":"Fanale","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bjh.14770","article-title":"The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer","volume":"179","author":"Flynn","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib40","first-page":"01281","article-title":"Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial","volume":"21","author":"Fornecker","year":"2022","journal-title":"J. Clin. Oncol. JCO"},{"key":"10.1016\/j.critrevonc.2023.103923_bib41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/0284186X.2019.1652765","article-title":"Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011-2016","volume":"59","author":"Foss\u00e5","year":"2020","journal-title":"Acta Oncol. Stockh. Swed."},{"key":"10.1016\/j.critrevonc.2023.103923_bib42","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/10428194.2019.1654100","article-title":"Retreatment with brentuximab vedotin in patients with relapsed\/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study","volume":"61","author":"Fukuhara","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2023.103923_bib43","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/annonc\/mdz009","article-title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)","volume":"30","author":"Garcia-Sanz","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib44","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2023.103923_bib45","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib46","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(21)00103-4","article-title":"Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study","volume":"8","author":"Hamadani","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-137451","article-title":"Preliminary results of a phase 2 study of Camidanlumab Tesirine (Cami), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in patients with relapsed or refractory Hodgkin lymphoma","volume":"136","author":"Herrera","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib48","doi-asserted-by":"crossref","first-page":"322","DOI":"10.6004\/jnccn.2022.0021","article-title":"NCCN Guidelines\u00ae Insights: Hodgkin Lymphoma, Version 2.2022: Featured Updates to the NCCN Guidelines","volume":"20","author":"Hoppe","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.critrevonc.2023.103923_bib49","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hon.2838","article-title":"Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 study","volume":"39","author":"Hutchings","year":"2021","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-019-0185-9","article-title":"Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma","volume":"9","author":"Jalali","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2023.103923_bib51","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/bjh.16201","article-title":"Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation","volume":"188","author":"Kaloyannidis","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib52","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/cancers12040877","article-title":"Prognostic Impact of tumor-associated macrophages on survival is checkpoint dependent in classical Hodgkin lymphoma","volume":"12","author":"Karihtala","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2023.103923_bib53","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2012-01-402792","article-title":"Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma","volume":"119","author":"Kasamon","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.critrevonc.2023.103923_bib54","first-page":"00276","article-title":"Outcomes related to FDG-PET-CT response in patients with Hodgkin lymphoma treated with brentuximab-vedotin at relapse or consolidation","volume":"S2152\u20132650","author":"Kedmi","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2023.103923_bib55","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2023.103923_bib56","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3324\/haematol.2019.243238","article-title":"Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC Transplant BRaVE study","volume":"106","author":"Kersten","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2023.103923_bib57","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib58","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib59","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/asheducation-2017.1.310","article-title":"Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma","volume":"2017","author":"Liu","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.critrevonc.2023.103923_bib60","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S2352-3026(21)00170-8","article-title":"Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1\/2 study","volume":"8","author":"Lynch","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib61","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.2022015423","article-title":"Response-adapted anti-PD-1\u2013based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib62","doi-asserted-by":"crossref","first-page":"32.e1","DOI":"10.1016\/j.jtct.2021.10.010","article-title":"Immune Reconstitution following high-dose chemotherapy and autologous stem cell transplantation with or without pembrolizumab maintenance therapy in patients with lymphoma","volume":"28","author":"Merryman","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.critrevonc.2023.103923_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.651288","article-title":"Autologous stem cell transplantation for myeloma: cytoreduction or an immunotherapy?","volume":"12","author":"Minnie","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib64","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/ajh.25871","article-title":"ABVD vs BEACOPP escalated in advanced-stage Hodgkin\u2019s lymphoma: results from a multicenter European study","volume":"95","author":"Mondello","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib65","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2009.07727.x","article-title":"Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma","volume":"146","author":"Moskowitz","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib66","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2019-122576","article-title":"Brentuximab vedotin and nivolumab for relapsed or refractory classic Hodgkin lymphoma: long-term follow-up results from the single-arm phase 1\/2 study","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib67","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib68","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.critrevonc.2023.103923_bib69","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib70","unstructured":"National Comprehensive Cancer Network (NCCN), 2022. Hodgkin Lymphoma, version 2.2022 NCCN Clinical Practice Guidelines in Oncology. \u3008https:\/\/nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf\u3009 (Accessed 28 Jul 2022)."},{"key":"10.1016\/j.critrevonc.2023.103923_bib71","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/pharmaceutics14061243","article-title":"Bispecific antibodies in cancer immunotherapy: a novel response to an old question","volume":"14","author":"Ord\u00f3\u00f1ez-Reyes","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2023.103923_bib72","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00277-019-03899-1","article-title":"Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience","volume":"99","author":"\u00d6zbalak","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib73","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s00277-018-3379-5","article-title":"Brentuximab vedotin as salvage treatment in Hodgkin lymphoma na\u00efve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP)","volume":"97","author":"Pavone","year":"2018","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib74","doi-asserted-by":"crossref","first-page":"91703","DOI":"10.18632\/oncotarget.18114","article-title":"Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed\/refractory Hodgkin\u2019s lymphoma","volume":"8","author":"Pellegrini","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2023.103923_bib75","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/17474086.2017.1270202","article-title":"Diagnostic, prognostic and therapeutic role of CD30 in lymphoma","volume":"10","author":"Pierce","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib76","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1007\/s00277-020-04204-1","article-title":"Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma","volume":"99","author":"Pincz\u00e9s","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib77","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1080\/0284186X.2018.1450522","article-title":"R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma","volume":"57","author":"Prusila","year":"2018","journal-title":"Acta Oncol. Stockh. Swed."},{"key":"10.1016\/j.critrevonc.2023.103923_bib78","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1158\/1078-0432.CCR-18-2435","article-title":"Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma","volume":"25","author":"Ramchandren","year":"2019","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2023.103923_bib79","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib80","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","author":"Ramos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib81","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.V101.2.420","article-title":"Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group","volume":"101","author":"Rehwald","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib82","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib83","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00277-019-03900-x","article-title":"Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience","volume":"99","author":"Roerden","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib84","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.858021","article-title":"Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed\/Refractory CD30+ Lymphoma","volume":"13","author":"Sang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib86","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2020-141250","article-title":"AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial","volume":"136","author":"Sasse","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib87","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib88","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12308-011-0104-x","article-title":"Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with CD30-positive lymphocyte-predominant (LP) cells","volume":"4","author":"Seliem","year":"2011","journal-title":"J. Hematop."},{"key":"10.1016\/j.critrevonc.2023.103923_bib89","first-page":"116","article-title":"Hodgkin lymphoma: A review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"Ca. Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2023.103923_bib90","first-page":"78","article-title":"Critical care management of chimeric antigen receptor T-cell therapy recipients","volume":"72","author":"Shimabukuro-Vornhagen","year":"2022","journal-title":"Ca. Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2023.103923_bib91","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"Ca. Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2023.103923_bib92","first-page":"CD007941","article-title":"Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma","volume":"5","author":"Skoetz","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.critrevonc.2023.103923_bib93","doi-asserted-by":"crossref","DOI":"10.1080\/17474086.2021.1942831","article-title":"Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed\/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma","author":"Song","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib94","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.3324\/haematol.2018.199844","article-title":"ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study","volume":"104","author":"Strati","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2023.103923_bib95","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib96","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib97","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/10428194.2019.1663419","article-title":"Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era","volume":"61","author":"Taparra","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2023.103923_bib98","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1080\/10428194.2019.1602262","article-title":"Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma","volume":"60","author":"von Tresckow","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2023.103923_bib99","first-page":"1141","article-title":"Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases","volume":"16","author":"Tzankov","year":"2003","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc."},{"key":"10.1016\/j.critrevonc.2023.103923_bib100","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","article-title":"Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL","volume":"131","author":"Vari","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.103923_bib101","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/bloodadvances.2021005385","article-title":"Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma","volume":"6","author":"Voorhees","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2023.103923_bib102","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2023.103923_bib103","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s11899-020-00589-y","article-title":"PD-1\/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas","volume":"15","author":"Xie","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.critrevonc.2023.103923_bib104","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cncr.11511","article-title":"A pilot study of rituximab in patients with recurrent, classic Hodgkin disease","volume":"98","author":"Younes","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2023.103923_bib105","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2023.103923_bib106","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib107","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2023.103923_bib108","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000860","article-title":"CD25-targeted antibody\u2013drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity","volume":"8","author":"Zammarchi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2023.103923_bib109","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood-2019-127280","article-title":"Three-year follow-up of keynote-087: pembrolizumab monotherapy in relapsed\/refractory classic Hodgkin lymphoma","volume":"134","author":"Zinzani","year":"2019","journal-title":"Blood"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823000112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823000112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:46:38Z","timestamp":1760903198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842823000112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":109,"alternative-id":["S1040842823000112"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103923","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103923","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103923"}}